Glycemic effects of vildagliptin and metformin combination therapy in Indian patients with type 2 diabetes: An observational study (印度2型糖尿病患者使用维格列汀与二甲双胍联合治疗对血糖的影响：一项观察性研究). (27th August 2013)

• Record Type: Journal Article
• Authors: Chatterjee, Sanjay; Chatterjee, Sudip
• Is Part Of: Journal of diabetes. Volume 6:Number 3(2014:Jul.)
• Page Start: 237
• Page End: 242
• Publication Date: 2013-08-27
• Subjects: Diabetes -- Periodicals; 618.3646005
• DOI: 10.1111/1753-0407.12078
• Languages: English
• ISSNs: 1753-0393

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <sec id="jdb12078-sec-0001" sec-type="section"> <title>Background</title> <p>To analyze the glycemic response of Indian patients with type2 diabetes mellitus (T2DM) to combination therapy with vildagliptin and metformin and compare our data with those of clinical trials.</p> </sec> <sec id="jdb12078-sec-0002" sec-type="section"> <title>Methods</title> <p>In a retrospective study of the hospital database, the glycemic control of 280 patients with T2DM who were either on a once‐ or twice‐daily regimen of combination therapy with vildagliptin 50 mg and metformin 500 mg was analyzed.</p> </sec> <sec id="jdb12078-sec-0003" sec-type="section"> <title>Results</title> <p>The mean duration of follow‐up of the patients was 16.8 months. There was a reduction in fasting plasma glucose (FPG) of 1.52 ± 0.79 and 1.88 ± 0.87 mmol/L in the once‐ and twice‐daily groups, respectively (both <italic>P</italic> < 0.0001) from baseline to last visit. The reduction in postprandial plasma glucose (PPPG) in the once‐ and twice‐daily groups was 3.98 ± 1.72 and 4.33 ± 1.88 mmol/L, respectively (both <italic>P</italic> < 0.0001), whereas the reduction in HbA1c was 1.41 ± 1.39% and 1.90 ± 1.49%, respectively (both <italic>P</italic> < 0.0001). The differences in the reductions achieved in FPG and HbA1c with the two dosing regimens were significant.</p> </sec> <sec id="jdb12078-sec-0004" sec-type="section"> <title>Conclusion</title> <p>Although the present retrospective study shows a robust response to the combination of vildagliptin and metformin in Indian patients, more multicenter studies from India with a greater number patients are necessary to confirm this finding.</p> </sec> </abstract>